Meryl Colton, MD MSc @mcolton_2 X Profile

Meryl Colton, MD MSc

@mcolton_2

Followers

279

Following

757

Media

13

Statuses

126

Medicine and public health. Lover of food, coffee, and mountains. Past CMR @CUInternalMed. Hematology/oncology fellow @UCSF

Joined November 2014

Don't wanna be here? Send us removal request.

Kalyan Nadiminti

@NadimintiHOBMT

4 months

Chimeric Antigen Receptor T-cell Therapy for Richter Transformation: A CIBMTR analysis - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy https://t.co/dhSabcV23o @MediHumdani @mshadman

4

7

16

Richard Riley (R²)

@Richard_D_Riley

4 months

New paper in BMJ (Research Methods & Reporting): “Dealing with continuous variables and modelling non-linear associations in healthcare data: practical guide” led by Pedro Lopez-Ayala & Tobias Zimmermann with @GSCollins & myself https://t.co/SAdnUoAHrf

bmj.com

Proper handling of continuous variables is crucial in healthcare research, for example, within regression modelling for descriptive, explanatory, or predictive purposes. However, inadequate methods...

2

36

132

Meryl Colton, MD MSc

@mcolton_2

5 months

Tough real world outcomes for bispecifics.

Ajay Major, MD, MBA

@majorajay

5 months

Bispecifics in R/R LBCL @BloodPortfolio: - 245 pts, 64% epcor, 60% prior CAR - mPFS 2.5 mos (!!!): 2.3 epcor, 3.8 glofi - mOS 7.8 mos overall (in MV model, glofi = better OS) - worse PFS/OS if trial ineligible & w/i 90 d of CAR Outcomes not great. #lymsm https://t.co/kE16kLV4jo

0

1

7

Raul Cordoba, MD, PhD #ASH25

@DrRaulCordoba

5 months

#Hematology Immunological consequences of #CARTcell therapy: an analysis of infectious complications and immune reconstitution | ⁦@BloodAdvances⁩ | American Society of Hematology #lymsm

ashpublications.org

Key PointsCAR T cells induce a cellular and humoral immunodeficiency resulting in an initial susceptibility for bacterial and later viral infections.Severe

1

18

55

Rahul Banerjee, MD, FACP

@RahulBanerjeeMD

5 months

👏 Tour de force analysis of SSQ-MM, a PRO measure focused on dexamethasone in myeloma #MMsm 100s of pts filled this out: common steroid AEs include insomnia but also prox myopathy (difficulty rising from 🪑). ⬆️ SSQ-MM strongly assoc with ⬇️ QOL. Time for #downwithdex!

Tracy King

@MMKingT

5 months

Building evidence to support burden of dex @gjmccaughan @jagger_jacqui @CNRU1 et al. Thanks for invitation @Maura1Dowling @SemOncNurs @RahulBanerjeeMD @Bethfaiman @mmamynurse Development and Validation of a Patient-Reported Outcome Measure to As...

2

3

6

Meryl Colton, MD MSc

@mcolton_2

6 months

Check out Dr Seshadri and my editorial on bridging therapy before CART —Bridging the Gap: Treatment Before CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma

dailynews.ascopubs.org

Bridging therapy plays an important role in the path to successful anti-CD19 CAR T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma. The choice of bridging therapy...

0

4

Mazyar Shadman, MD MPH

@mshadman

1 year

Just out! Excited about our @JCO_ASCO manuscript published concurrently with our #ASH24 presentation. @fredhutch #CLL Zanubrutinib vs. BR in Patients with TN CLL/SLL: Median 5-Year Follow-Up of SEQUOIA | Journal of Clinical Oncology

ascopubs.org

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or...

0

12

68

Ajay Major, MD, MBA

@majorajay

1 year

Retrospective maint R TRIANGLE #ASH24 - propensity scoring: PFS superior with RM - benefit of RM across all arms for PFS - no diff in OS - MV for p53: PFS benefit still seen - more infx with RM across all arms (none G5) BTKi + R maintenance for 1L MCL after induction. #lymsm

0

6

20

Eddie Cliff

@Eddie_Cliff

1 year

Next up, CD22-CAR T from @StanfordMed 3 year follow up, 37/38 prior CR19 CAR T Durable responses in one third of patients Higher rates of SPMs - ?impact of 2x rounds of lymphodepletion Good to see many presenters reporting NRM #ASH24 #lymsm #TCellRx @AshAlizadeh

1

7

16

Eddie Cliff

@Eddie_Cliff

1 year

ENRICH: ibrutinib+R vs BR or RCHOP IR better PFS than RCHOP but *not* better than BR Reasonable to consider BTKi first line in patient who prefers to avoid benda but I suspect unlikely to be cost effective given continuous therapy #ASH24 #lymsm

1

7

20

Jordan Gauthier

@drjgauthier

1 year

Very excited to share our work led by @emilyliangmd just published in @BloodAdvances! https://t.co/m1v1U3bWGI We used the {tidymodels} framework in R to develop models (eIPM) predictive of hematotoxicity in CAR T-cell therapy recipients. Models performed well in our independent

Emily Liang

@emilyliangmd

1 year

Thanks to @BloodAdvances for publishing our work to develop and validate the Early ICAHT Prediction Models (eIPMs)! The eIPMs predict the probability of severe (grade 3-4) early ICAHT per the EHA/EBMT criteria across B- and plasma cell malignancies. https://t.co/v9WhTP2fDo (1/4)

5

19

69

manalikamdar

@mana1981

1 year

Excited to share the stage with Drs. Nathan Fowler and Paolo Strati at the Satellite Symposium during #ASH24!Don’t miss it—sign up now to join the discussion! #LymphomaResearch @CULymphoma @CUHematology @CUAnschutz @ASH_hematology

PRIME Education

@PRIME_cme

1 year

Live @ ASH 2024! | Treatment Crossroads: Diverse Perspectives on Treatment Strategies for Relapsed/Refractory DLBCL and FL | Attend In-person or Virtually #MedEd #livecredit #ASH2024 #DLBCLTreatment #FollicularLymphoma #CAR-TCellTherapy | @mana1981 | https://t.co/OntyhMnLXW

0

3

9

Mehdi Hamadani, MD

@MediHumdani

1 year

Impressive 3-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies. Median PFS 24mons, median OS NR #lymsm

ashpublications.org

Key PointsThree-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies showed long-lasting remissions and meaningful survival outcomes.Manageab

0

4

15

Meryl Colton, MD MSc

@mcolton_2

1 year

👀👀👀

Blood Journals Portfolio

@BloodPortfolio

1 year

Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy https://t.co/225o6hQqbW #immunobiologyandimmunotherapy #lymphoidneoplasia

0

1

Toby Eyre

@tobyeyre82

1 year

ENRICH Primary analysis 4y fup R-Ibrutinib vs R-chemo (BR or RCHOP) 1L #MCL IR superior PFS to ICT HR 0.69 p=0.003 ⬇️ haem tox Earlier ⬆️QoL with R-Ibr Major benefit seen vs RCHOP subgrp 1st 1L RCT across any lymphoma (not incl CLL) showing non-chemo superior to ICT #ASH2024

3

32

78

Paul Bröckelmann

@BroeckelmannPJ

1 year

Just in time for #ISHL13 a comprehensive review on Hodgkin lymphoma biology and implications for translational research is now available @TrendsMolecMed, masterfully authored by Ralf Küppers @unidue #SFB1530 https://t.co/WnqjvV3Cc4

2

11

43

Toby Eyre

@tobyeyre82

1 year

Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation

ashpublications.org

Key PointsBOVen was safe and effective for the frontline treatment of TP53-mutant MCL.The 2-year progression-free survival of 72% compares favorably with p

1

24

93

Jonathan Friedberg

@DrJFriedberg

1 year

Long awaited IELSG37 Trial Results: Patients with mediastinal large B-cell lymphoma who achieve Deauville scores of 1-3 on PET after immunochemotherapy have excellent outcomes and do not require consolidative radiation therapy. @JCO_ASCO https://t.co/QfIIXL4FAf

ascopubs.org

PURPOSEThe role of consolidation radiotherapy in patients with primary mediastinal B-cell lymphoma (PMBCL) is controversial.METHODSThe IELSG37 trial, a randomized noninferiority study, aimed to...

1

22

57

Meryl Colton, MD MSc

@mcolton_2

1 year

Great characterization of another long term toxicity after CAR-T for myeloma. @UCSFCancer

Rahul Banerjee, MD, FACP

@RahulBanerjeeMD

1 year

1/ 🚨 Now in @BloodCancerJnl - our multicenter description of IEC-associated enterocolitis as a novel toxicity of CAR-T in myeloma #MMsm. Typically non-bloody Gr3+ diarrhea starting ~3 mo after ide-cel or cilta-cel: 36% cases fatal in our series (n=14). https://t.co/hM5gsdk8J9

1

3

NEJM

@NEJM

1 year

In patients with advanced-stage Hodgkin’s lymphoma, nivolumab added to chemotherapy resulted in greater 2-year progression-free survival than the addition of brentuximab vedotin to chemotherapy. Full trial results: https://t.co/BdiBCue4dt

1

47

130